JP7599228B2 - Ｒｅｔキナーゼ阻害剤としての化合物およびその応用 - Google Patents

Ｒｅｔキナーゼ阻害剤としての化合物およびその応用 Download PDF

Info

Publication number
JP7599228B2
JP7599228B2 JP2022571184A JP2022571184A JP7599228B2 JP 7599228 B2 JP7599228 B2 JP 7599228B2 JP 2022571184 A JP2022571184 A JP 2022571184A JP 2022571184 A JP2022571184 A JP 2022571184A JP 7599228 B2 JP7599228 B2 JP 7599228B2
Authority
JP
Japan
Prior art keywords
group
compound
mmol
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022571184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525933A (ja
Inventor
リー，ジュン
チェン，マオリン
ニウ，チョンシャン
リィアン，アペン
ウー，ユーシェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TYK Medicines Inc
Original Assignee
TYK Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TYK Medicines Inc filed Critical TYK Medicines Inc
Publication of JP2023525933A publication Critical patent/JP2023525933A/ja
Application granted granted Critical
Publication of JP7599228B2 publication Critical patent/JP7599228B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022571184A 2020-05-20 2021-05-07 Ｒｅｔキナーゼ阻害剤としての化合物およびその応用 Active JP7599228B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010432188.2 2020-05-20
CN202010432188 2020-05-20
CN202011315155.6 2020-11-20
CN202011315155 2020-11-20
PCT/CN2021/092202 WO2021233133A1 (zh) 2020-05-20 2021-05-07 用作ret激酶抑制剂的化合物及其应用

Publications (2)

Publication Number Publication Date
JP2023525933A JP2023525933A (ja) 2023-06-19
JP7599228B2 true JP7599228B2 (ja) 2024-12-13

Family

ID=78647886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571184A Active JP7599228B2 (ja) 2020-05-20 2021-05-07 Ｒｅｔキナーゼ阻害剤としての化合物およびその応用

Country Status (10)

Country Link
US (1) US12545681B2 (de)
EP (1) EP4155304B9 (de)
JP (1) JP7599228B2 (de)
KR (1) KR102841446B1 (de)
CN (1) CN113698390B (de)
AU (1) AU2021276206B2 (de)
CA (1) CA3179612A1 (de)
ES (1) ES3059451T3 (de)
TW (1) TWI782523B (de)
WO (1) WO2021233133A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111961034A (zh) * 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用
CN115894482A (zh) * 2022-11-09 2023-04-04 深圳长铭医药有限公司 Ret抑制剂及其制备方法与应用
WO2024234384A1 (zh) 2023-05-18 2024-11-21 浙江同源康医药股份有限公司 一种嘧啶并氮杂环类化合物的晶型及其制备方法及应用
CN116763930A (zh) * 2023-07-03 2023-09-19 中国海洋大学 Shp2抑制剂联合肿瘤治疗药物在肿瘤耐药中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525422A (ja) 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JP2018535967A (ja) 2015-11-02 2018-12-06 ブループリント メディシンズ コーポレイション Ｒｅｔの阻害剤
JP2022534067A (ja) 2019-05-20 2022-07-27 ティーワイケー メディシンズ インコーポレーテッド Ｒｅｔキナーゼ阻害剤としての化合物およびその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499519B2 (en) * 2012-12-26 2016-11-22 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
UA115388C2 (uk) * 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
TWI752098B (zh) * 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136661A1 (en) * 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
CN111285882B (zh) * 2018-12-07 2022-12-02 四川科伦博泰生物医药股份有限公司 稠环化合物、包含其的药物组合物及其制备方法和用途
WO2020175968A1 (ko) * 2019-02-28 2020-09-03 주식회사 보로노이 N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 약학적 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525422A (ja) 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
JP2018535967A (ja) 2015-11-02 2018-12-06 ブループリント メディシンズ コーポレイション Ｒｅｔの阻害剤
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JP2022534067A (ja) 2019-05-20 2022-07-27 ティーワイケー メディシンズ インコーポレーテッド Ｒｅｔキナーゼ阻害剤としての化合物およびその使用

Also Published As

Publication number Publication date
EP4155304A4 (de) 2024-05-29
JP2023525933A (ja) 2023-06-19
KR102841446B1 (ko) 2025-07-31
KR20230015944A (ko) 2023-01-31
WO2021233133A1 (zh) 2021-11-25
EP4155304A1 (de) 2023-03-29
TWI782523B (zh) 2022-11-01
AU2021276206A1 (en) 2023-02-02
ES3059451T3 (en) 2026-03-20
CN113698390A (zh) 2021-11-26
AU2021276206B2 (en) 2024-12-12
EP4155304B1 (de) 2025-12-17
CN113698390B (zh) 2022-09-27
US12545681B2 (en) 2026-02-10
CA3179612A1 (en) 2021-11-25
EP4155304B9 (de) 2026-04-15
US20230234954A1 (en) 2023-07-27
TW202144358A (zh) 2021-12-01

Similar Documents

Publication Publication Date Title
JP7599228B2 (ja) Ｒｅｔキナーゼ阻害剤としての化合物およびその応用
JP7607342B2 (ja) Ｒｅｔキナーゼ阻害剤としての化合物およびその使用
AU2022200478B2 (en) Inhibitors of KEAP1-Nrf2 protein-protein interaction
WO2023179629A1 (zh) 取代桥环类抑制剂及其制备方法和应用
WO2022199586A1 (zh) 嘧啶并吡啶类抑制剂及其制备方法和应用
JP6930748B2 (ja) キナゾリン誘導体、そのための調製方法、医薬組成物、および適用
TW202003466A (zh) 人類整合素α４β７拮抗劑
JP7481435B2 (ja) Ｃｒａｃ阻害剤としての２ｈ－ベンゾピラン誘導体
TW202340198A (zh) 靶向ｍａｌｔ１的蛋白降解化合物、包含其的醫藥組合物及其用途
WO2021129841A1 (zh) 用作ret激酶抑制剂的化合物及其应用
WO2025108336A1 (zh) 用于egfr蛋白降解的化合物及其用途
CN102532114B (zh) 烟酸衍生物,其制备方法及其药物组合物
CN116813646A (zh) 取代桥环类抑制剂及其制备方法和应用
HK40090211A (en) Compound used as ret kinase inhibitor and application thereof
HK40090211B (en) Compound used as ret kinase inhibitor and application thereof
HK40120225A (zh) 用於egfr蛋白降解的化合物及其用途
CN118772107A (zh) Hdac抑制剂及其用途
CN121039147A (zh) 一种短肽类化合物及其制备方法和医药应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240815

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241126

R150 Certificate of patent or registration of utility model

Ref document number: 7599228

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150